Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2972)	6/24/2010 11:17:46 AM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

IDRA is up 6.33% on volume still below its ADV bigcharts.marketwatch.com The stock is trying to get off from the near-term DT coming from its Apr15 H at $7.32 <g> bigcharts.marketwatch.com IDRA announced this week that Eve E. Slater, M.D., F.A.C.C., has joined its Board of Directors as a class III director. Dr. Slater has extensive experience in the pharmaceutical industry, recently serving as senior vice president for worldwide policy at PFE. She had previously held senior management positions at MRK Research Labs., and was the Assistant Secretary for Health and served as chief health policy advisor for the U.S. DHHS. She said that IDRA has created a pretty good pipeline with drugs candidates for treatment of a broad range of diseases and that she may be able to help with her clinical and regulatory experience to advance IDRA's pipeline.<g> The ACTAY is $11.67 IDRA has NLTD and +CF It started the Yr. with lower revenues and higher L on the 1stQ The L for 2010 ^ 2011 are expected around $0.06 & $0,11 vs. $0.31 on the black in 2009 There is a good amount of resistance at the $4 and $5 levels Although IDRA has plenty of room to run, I think I will put a TT at the $4.90 level pending further developments. <g> bigcharts.marketwatch.com Bernard